Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R2VL
|
|||
| Former ID |
DNC007882
|
|||
| Drug Name |
6-(2-benzylisoindolin-5-yloxy)nicotinamide
|
|||
| Synonyms |
CHEMBL238362; 6-(2-benzylisoindolin-5-yloxy)nicotinamide; SCHEMBL3690327; GGVSFVBTUMOASO-UHFFFAOYSA-N; BDBM50226248
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19N3O2
|
|||
| Canonical SMILES |
C1C2=C(CN1CC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
|
|||
| InChI |
1S/C21H19N3O2/c22-21(25)16-7-9-20(23-11-16)26-19-8-6-17-13-24(14-18(17)10-19)12-15-4-2-1-3-5-15/h1-11H,12-14H2,(H2,22,25)
|
|||
| InChIKey |
GGVSFVBTUMOASO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.